Smith D J, King W F, Barnes L A, Trantolo D, Wise D L, Taubman M A
Department of Immunology, The Forsyth Institute, Boston, Massachusetts 02115, USA.
Infect Immun. 2001 Aug;69(8):4767-73. doi: 10.1128/IAI.69.8.4767-4773.2001.
Synthetic peptide vaccines which are derived from functional domains of Streptococcus mutans glucosyltransferases (GTF) have been shown to induce protective immunity in Sprague-Dawley rats after subcutaneous injection in the salivary gland region. Since mucosal induction of salivary immunity would be preferable in humans, we explored methods to induce mucosal antibody in the rat to the GTF peptide vaccines HDS and HDS-GLU after intranasal administration. Several methods of facilitation of the immune response were studied: the incorporation of peptides in bioadhesive poly(D,L-lactide-coglycolide) (PLGA) microparticles, the use of monoepitopic (HDS) or diepitopic (HDS-GLU) peptide constructs, or the use of mucosal adjuvants. Salivary immunoglobulin A (IgA) responses were not detected after intranasal administration of diepitopic HDS-GLU peptide constructs in alum or after incorporation into PLGA microparticles. However, significant primary and secondary salivary IgA and serum IgG antibody responses to HDS were induced in all rats when cholera holotoxin (CT) or a detoxified mutant Escherichia coli heat-labile enterotoxin (R192G LT) were intranasally administered with HDS peptide constructs in PLGA. Coadministration of LT with HDS resulted in predominantly IgG2a responses in the serum, while coadministration with CT resulted in significant IgG1 and IgG2a responses to HDS. Serum IgG antibody, which was induced to the HDS peptide construct by coadministration with these adjuvants, also bound intact mutans streptococcal GTF in an enzyme-linked immunosorbent assay and inhibited its enzymatic activity. Thus, immune responses which are potentially protective for dental caries can be induced to peptide-based GTF vaccines after mucosal administration if combined with the CT or LT R192G mucosal adjuvant.
源自变形链球菌葡糖基转移酶(GTF)功能域的合成肽疫苗,经皮下注射至唾液腺区域后,已在斯普拉格-道利大鼠中显示出能诱导保护性免疫。由于在人类中诱导唾液免疫的黏膜途径更为可取,我们探索了在大鼠中经鼻内给药后诱导其对GTF肽疫苗HDS和HDS-GLU产生黏膜抗体的方法。研究了几种促进免疫反应的方法:将肽掺入生物黏附性聚(D,L-丙交酯-共-乙交酯)(PLGA)微粒中、使用单表位(HDS)或双表位(HDS-GLU)肽构建体,或使用黏膜佐剂。在鼻内给予明矾中的双表位HDS-GLU肽构建体或掺入PLGA微粒后,未检测到唾液免疫球蛋白A(IgA)反应。然而,当霍乱全毒素(CT)或解毒的突变型大肠杆菌不耐热肠毒素(R192G LT)与PLGA中的HDS肽构建体经鼻内共同给药时,所有大鼠均诱导出对HDS的显著初次和二次唾液IgA及血清IgG抗体反应。LT与HDS共同给药导致血清中主要为IgG2a反应,而与CT共同给药导致对HDS有显著的IgG1和IgG2a反应。通过与这些佐剂共同给药诱导产生的针对HDS肽构建体的血清IgG抗体,在酶联免疫吸附测定中也能结合完整的变形链球菌GTF并抑制其酶活性。因此,如果与CT或LT R192G黏膜佐剂联合使用,经黏膜给药后可诱导对基于肽的GTF疫苗产生潜在预防龋齿的免疫反应。